Identity recordUS research-market identity with a separate FDA-approved medicine record
What PT-141 / Bremelanotide resolves to
This record resolves seller-labelled 10 mg PT-141 research listings. VYLEESI is a separate FDA-approved bremelanotide prescription product with a 1.75 mg presentation, defined indication, label, and regulated supply chain. The research listings do not inherit that approval.
- Evidence lane
- Research price board
- Current record
- 2 of 3 rows in stock
- Checked
- Jul 23, 2026
PT 141BremelanotideVyleesi
Destination recordConsulta en registros de ANMAT
What Argentina still has to prove
Guía argentina para investigar nombres de péptidos sin confundir una coincidencia de ingrediente, una oferta importada o una etiqueta de investigación con un medicamento registrado y una vía de suministro verificada.
- Comparison mode
- ARS / medicamento, titular y establecimiento
- Price coverage
- Sin tabla comercial calificada para Argentina
- Guide updated
- 18 de julio de 2026